Loading
A phase 3 trial testing TQB3616 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer is a phase 3 interventional study registered as NCT05780567, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting on the registry. Official title: Randomised, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of TQB3616 Combined With Endocrine Therapy Versus Placebo Combined With Endocrine Therapy in Hormone Receptors (HR)-Positive and Human Epidermal GrowthFactor Receptor-2 (HER2) -Negative Breast Cancer Adjuvant Therapy. Planned enrolment is 1946 participants (estimated). The study started in 2023-03-30 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
Shares TQB3616, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares High-risk early HR-positive breast cancer, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer.